NASDAQ:NMTR

9 Meters Biopharma Competitors

$1.15
-0.04 (-3.36 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.15
Now: $1.15
$1.20
50-Day Range
$1.11
MA: $1.55
$1.94
52-Week Range
$0.44
Now: $1.15
$2.26
Volume2.50 million shs
Average Volume10.87 million shs
Market Capitalization$248.48 million
P/E RatioN/A
Dividend YieldN/A
Beta0.11

Competitors

9 Meters Biopharma (NASDAQ:NMTR) Vs. PAHC, ENTA, ARCT, AKRO, EPIX, and ANNX

Should you be buying NMTR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to 9 Meters Biopharma, including Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Arcturus Therapeutics (ARCT), Akero Therapeutics (AKRO), ESSA Pharma (EPIX), and Annexon (ANNX).

Phibro Animal Health (NASDAQ:PAHC) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Volatility & Risk

Phibro Animal Health has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500.

Valuation and Earnings

This table compares Phibro Animal Health and 9 Meters Biopharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phibro Animal Health$800.40 million1.24$33.55 million$1.0822.72
9 Meters BiopharmaN/AN/A$-27,050,000.00N/AN/A

Phibro Animal Health has higher revenue and earnings than 9 Meters Biopharma.

Institutional and Insider Ownership

50.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 19.9% of 9 Meters Biopharma shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 26.7% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Phibro Animal Health and 9 Meters Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Phibro Animal Health11001.50
9 Meters Biopharma00703.00

Phibro Animal Health presently has a consensus target price of $21.50, suggesting a potential downside of 12.39%. 9 Meters Biopharma has a consensus target price of $5.00, suggesting a potential upside of 334.78%. Given 9 Meters Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe 9 Meters Biopharma is more favorable than Phibro Animal Health.

Profitability

This table compares Phibro Animal Health and 9 Meters Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Phibro Animal Health5.37%23.70%5.99%
9 Meters BiopharmaN/AN/A-258.66%

Summary

Phibro Animal Health beats 9 Meters Biopharma on 8 of the 11 factors compared between the two stocks.

9 Meters Biopharma (NASDAQ:NMTR) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

9 Meters Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Earnings and Valuation

This table compares 9 Meters Biopharma and Enanta Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A$-27,050,000.00N/AN/A
Enanta Pharmaceuticals$122.47 million8.03$-36,170,000.00($0.89)-54.78

9 Meters Biopharma has higher earnings, but lower revenue than Enanta Pharmaceuticals.

Insider & Institutional Ownership

19.9% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are held by institutional investors. 26.7% of 9 Meters Biopharma shares are held by insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for 9 Meters Biopharma and Enanta Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
9 Meters Biopharma00703.00
Enanta Pharmaceuticals13302.29

9 Meters Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 334.78%. Enanta Pharmaceuticals has a consensus price target of $65.2857, suggesting a potential upside of 33.92%. Given 9 Meters Biopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe 9 Meters Biopharma is more favorable than Enanta Pharmaceuticals.

Profitability

This table compares 9 Meters Biopharma and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
9 Meters BiopharmaN/AN/A-258.66%
Enanta Pharmaceuticals-29.53%-3.75%-3.53%

Summary

9 Meters Biopharma beats Enanta Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

9 Meters Biopharma (NASDAQ:NMTR) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

9 Meters Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.01, indicating that its share price is 201% more volatile than the S&P 500.

Earnings and Valuation

This table compares 9 Meters Biopharma and Arcturus Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A$-27,050,000.00N/AN/A
Arcturus Therapeutics$20.79 million46.77$-25,990,000.00($2.15)-17.21

Arcturus Therapeutics has higher revenue and earnings than 9 Meters Biopharma.

Insider & Institutional Ownership

19.9% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 74.3% of Arcturus Therapeutics shares are held by institutional investors. 26.7% of 9 Meters Biopharma shares are held by insiders. Comparatively, 12.6% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for 9 Meters Biopharma and Arcturus Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
9 Meters Biopharma00703.00
Arcturus Therapeutics25402.18

9 Meters Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 334.78%. Arcturus Therapeutics has a consensus price target of $70.6667, suggesting a potential upside of 90.99%. Given 9 Meters Biopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe 9 Meters Biopharma is more favorable than Arcturus Therapeutics.

Profitability

This table compares 9 Meters Biopharma and Arcturus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
9 Meters BiopharmaN/AN/A-258.66%
Arcturus Therapeutics-506.70%-52.32%-33.21%

Summary

9 Meters Biopharma beats Arcturus Therapeutics on 6 of the 11 factors compared between the two stocks.

9 Meters Biopharma (NASDAQ:NMTR) and Akero Therapeutics (NASDAQ:AKRO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

9 Meters Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Earnings and Valuation

This table compares 9 Meters Biopharma and Akero Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A$-27,050,000.00N/AN/A
Akero TherapeuticsN/AN/A$-43,760,000.00($2.90)-9.57

Insider & Institutional Ownership

19.9% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 83.5% of Akero Therapeutics shares are held by institutional investors. 26.7% of 9 Meters Biopharma shares are held by insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for 9 Meters Biopharma and Akero Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
9 Meters Biopharma00703.00
Akero Therapeutics00703.00

9 Meters Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 334.78%. Akero Therapeutics has a consensus price target of $57.2857, suggesting a potential upside of 106.36%. Given 9 Meters Biopharma's higher probable upside, equities research analysts plainly believe 9 Meters Biopharma is more favorable than Akero Therapeutics.

Profitability

This table compares 9 Meters Biopharma and Akero Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
9 Meters BiopharmaN/AN/A-258.66%
Akero TherapeuticsN/A-40.84%-38.33%

Summary

9 Meters Biopharma beats Akero Therapeutics on 4 of the 7 factors compared between the two stocks.

9 Meters Biopharma (NASDAQ:NMTR) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Risk & Volatility

9 Meters Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500.

Earnings and Valuation

This table compares 9 Meters Biopharma and ESSA Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A$-27,050,000.00N/AN/A
ESSA PharmaN/AN/A$-23,440,000.00($1.04)-27.28

Insider & Institutional Ownership

19.9% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 63.4% of ESSA Pharma shares are held by institutional investors. 26.7% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for 9 Meters Biopharma and ESSA Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
9 Meters Biopharma00703.00
ESSA Pharma00503.00

9 Meters Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 334.78%. ESSA Pharma has a consensus price target of $28.80, suggesting a potential upside of 1.52%. Given 9 Meters Biopharma's higher probable upside, equities research analysts plainly believe 9 Meters Biopharma is more favorable than ESSA Pharma.

Profitability

This table compares 9 Meters Biopharma and ESSA Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
9 Meters BiopharmaN/AN/A-258.66%
ESSA PharmaN/A-46.31%-45.08%

9 Meters Biopharma (NASDAQ:NMTR) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Earnings and Valuation

This table compares 9 Meters Biopharma and Annexon's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A$-27,050,000.00N/AN/A
AnnexonN/AN/A$-37,180,000.00N/AN/A

Insider & Institutional Ownership

19.9% of 9 Meters Biopharma shares are held by institutional investors. Comparatively, 91.2% of Annexon shares are held by institutional investors. 26.7% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for 9 Meters Biopharma and Annexon, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
9 Meters Biopharma00703.00
Annexon00503.00

9 Meters Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 334.78%. Annexon has a consensus price target of $34.3333, suggesting a potential upside of 37.72%. Given 9 Meters Biopharma's higher probable upside, equities research analysts plainly believe 9 Meters Biopharma is more favorable than Annexon.

Profitability

This table compares 9 Meters Biopharma and Annexon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
9 Meters BiopharmaN/AN/A-258.66%
AnnexonN/A-566.22%-32.99%

Summary

9 Meters Biopharma beats Annexon on 5 of the 7 factors compared between the two stocks.


9 Meters Biopharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.54-0.1%$992.72 million$800.40 million23.15News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.75-1.1%$983.39 million$122.47 million-26.79News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$37.00-1.8%$972.36 million$20.79 million-12.76
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.76-1.9%$965.22 millionN/A-12.79
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.37-0.2%$958.34 millionN/A-26.27News Coverage
Annexon logo
ANNX
Annexon
1.9$24.93-0.9%$951.28 millionN/A0.00
Humanigen logo
HGEN
Humanigen
1.6$17.25-1.9%$922.56 millionN/A0.00
Radius Health logo
RDUS
Radius Health
1.3$19.49-2.0%$913.96 million$173.32 million-7.99News Coverage
Prothena logo
PRTA
Prothena
2.3$22.78-3.1%$911.34 million$810,000.00-8.90News Coverage
Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25-2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Gap Down
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$35.87-0.4%$881.43 millionN/A-10.64Analyst Report
News Coverage
Gap Down
Merus logo
MRUS
Merus
1.6$23.06-1.0%$879.21 million$31.13 million-7.51Analyst Report
Analyst Revision
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$16.75-0.0%$861.92 millionN/A0.00
Affimed logo
AFMD
Affimed
1.6$9.74-19.0%$860.30 million$23.96 million-16.51High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
Epizyme logo
EPZM
Epizyme
1.8$8.37-0.6%$851.94 million$23.80 million-3.75
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.89-0.6%$848.58 million$322.36 million127.79
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.33-1.3%$810.86 million$296.70 million47.61
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.57-7.5%$791.51 millionN/A0.00Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37-1.1%$775.18 million$322.07 million-5.11
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$26.95-4.7%$753.06 million$148.36 million-7.00Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.02-1.2%$747.83 million$40.89 million-3.46
Veru logo
VERU
Veru
1.4$10.35-0.3%$744.29 million$42.59 million-36.96
Ardelyx logo
ARDX
Ardelyx
1.6$7.44-5.6%$734.18 million$5.28 million-7.37Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27Gap Down
Chimerix logo
CMRX
Chimerix
1.3$8.45-2.1%$723.99 million$12.52 million-14.82News Coverage
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.82-1.8%$716.29 million$2.22 million-16.59
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$3.05-3.3%$708.43 million$64.61 million-4.49Upcoming Earnings
Analyst Upgrade
Gap Down
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.50-0.0%$686.58 million$19.56 million-19.78High Trading Volume
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.74-3.3%$660.12 millionN/A-2.46Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$28.38-13.7%$655.29 million$13.80 million-13.71Insider Selling
High Trading Volume
News Coverage
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23-5.6%$651.22 million$143.01 million-1.19Gap Down
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$19.86-9.5%$640.68 millionN/A-10.56Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$26.15-0.1%$635.65 million$12.69 million-12.57
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$17.62-1.3%$630.96 million$6.83 million-18.16News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.66-5.2%$628.85 million$5.09 million-6.10Analyst Upgrade
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.88-2.4%$628.47 million$9.64 million-5.36
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.82-3.0%$624.78 million$17.26 million-4.12Earnings Announcement
Analyst Revision
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$12.32-9.9%$598.21 millionN/A-6.32Analyst Upgrade
News Coverage
Gap Down
Evolus logo
EOLS
Evolus
1.1$13.58-2.4%$593.89 million$34.92 million-6.69Analyst Report
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$35.23-2.0%$590.00 millionN/A-16.31Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$20.87-6.3%$571.13 million$8 million-7.70Gap Down
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.04-4.1%$568.85 millionN/A-9.33Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.52-3.3%$567.69 millionN/A-4.47News Coverage
Gap Up
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.07-4.9%$563.81 million$1.19 million-7.11Insider Buying
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
0.0$14.44-2.2%$557.76 millionN/A0.00Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26-1.8%$554.59 million$59.29 million-21.73
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.20-5.2%$553.64 millionN/A-5.29Analyst Upgrade
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$41.56-0.9%$549.30 million$195.89 million118.75News Coverage
SIGA
SIGA Technologies
0.3$7.10-0.6%$544.91 million$26.74 million17.75
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.